Silence Therapeutics (LON:SLN) posted its quarterly earnings data on Monday. The company reported GBX (13.70) (($0.18)) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of GBX (21.70) (($0.28)) by GBX 8 ($0.10), Digital Look Earnings reports.
Shares of LON:SLN traded down GBX 5 ($0.07) during midday trading on Monday, reaching GBX 463 ($6.05). The company had a trading volume of 64,817 shares, compared to its average volume of 182,641. The company’s 50 day moving average price is GBX 466.62 and its 200 day moving average price is GBX 445.10. The company has a current ratio of 3.88, a quick ratio of 3.84 and a debt-to-equity ratio of 1.37. The stock has a market cap of $383.49 million and a P/E ratio of -17.74. Silence Therapeutics has a 52-week low of GBX 161 ($2.10) and a 52-week high of GBX 646.50 ($8.45).
Separately, Peel Hunt reaffirmed a “buy” rating on shares of Silence Therapeutics in a report on Thursday, July 16th.
Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various candidates for the treatment of cancer, iron overload disorders, cardiovascular disease, alcohol use disorder, and other metabolic diseases.
Read More: What is the Ex-Dividend Date in Investing?
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.